Surgery Pharmacy Services, Inc., Chattanooga, TN

Is Surgery Pharmacy Services, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Surgery Pharmacy Services, Inc. hold a Tennessee pharmacy license?

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions.

Has Surgery Pharmacy Services, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Oct 9, 2020) for Surgery Pharmacy Services, Inc. State board actions: no Tennessee Board of Pharmacy action under this exact name and city was found in the Board of Pharmacy sections of the Tennessee Department of Health’s monthly Disciplinary Action Reports (actions dated January 2004 to April 2026) on Nov 15, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Surgery Pharmacy Services, Inc.
Location
Chattanooga, TN
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Jul 14, 2023
FDA Data Dashboard inspections
2 inspections: 2 OAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 13 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Surgery Pharmacy Services, Inc., a 503A facility, with 4 dated actions.

Document
Jul 14, 2023Response to Form 483483 Response Letter Issued 07/14/2023FDA copy (archived)
Jul 7, 2023Form 483483 Issued 07/07/2023FDA copy (archived)
Oct 9, 2020Warning letterWarning Letter (10/09/2020)FDA copy (archived)
Dec 6, 2019Form 483483 Issued 12/06/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Surgery Pharmacy Services Inc, Chattanooga, TN (FEI number 3010704905), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jul 7, 2023Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30107049051209620
Dec 6, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30107049051115413

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 13 numbered observations in all, across 2 inspections ending Dec 6, 2019 to Jul 7, 2023. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jun 20, 2023 to Jul 7, 2023: 3 observations

Firm on the cover
Surgery Pharmacy Services Inc, 3908 Tennessee Ave Ste F, Chattanooga, TN 37409-1357
FEI number
010704905
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
DISTRIC T ADDRESS AND PHONE NUMBER 60 Eighth Street NE Atlanta, GA 30309
Matched to this page by
firm name, city and state on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Smoke studies were inadequately performed under dynamic conditions.

Specifically, your videos of the smoke studies conducted on April 13, 2023 do not show manipulations or conditions performed that would be representative of the dynamic process used in actual compounding processes using the <Redacted B4> <Redacted B4>

For example, the <Redacted B4> additions of volumes deemed too small to be added to the final products; the connection of the TPN bag to the tubing, the powered on state of the <Redacted B4> and scale; and connections made to all <Redacted B4> component stations are not performed during the smoke study.

i

Observation 2

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Specifically, your media fills are not representative of production in that manipulations made during production are not reproduced with the media fill process. For example, manipulations not represented are the addition of volumes deemed too small for inclusion via the <Redacted B4> machine.

Observation 3

Your facility is designed and operated in a way that may permit the influx of lesser quality air into a higher quality air area.

Specifically, material flows directly from an unclassified area into a ISO 7 classified room in which sterile production occurs via <Redacted B4> which consists of <Redacted B4> with a <Redacted B4>.

On 06/21/2023, materials were used in compounding total parenteral nutrition (TPN) products that included a calibration kit, tubing, and bags which had entered the ISO 7 area via the <Redacted B4> well as finished TPN products leaving the ISO 7 area into the unclassified space via this unfiltered <Redacted B4>. This <Redacted B4> is located within close proximity, approximately three feet, to an ISO 5 hood used in sterile compounding of TPN products.

Inspection Nov 18, 2019 to Dec 6, 2019: 10 observations

Firm on the cover
Surgery Pharmacy Services, Inc., 3908 Tennessee Avenue, Suite F, Chattanooga, TN 37409
FEI number
3010704905
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
Pharma Division II 404 BNA Drive, Building 200, Suite 500 Nashville, TN 37217
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Actionable microbial contamination was present in the ISO 5 area or in adjacent areas during aseptic production without adequate product evaluation and remedial action. Specifically, on 5/27/2019, the response to Bacillus microbial contamination within ISO 5 Hood <Redacted B4> did not include testing to determine the extent of impact nor identification and notification of all potentially impacted patients.

Observation 2

Personnel failed to disinfect or change gloves frequently enough to prevent contamination. Specifically, the technician was observed to disinfect her gloves infrequently during sterile production of TPN products on 11/18/2019. For example, she was observed to move her hands outside of the ISO 5 hood and then back into the hood without sanitization. On 11/19/2019, the technician was observed tying out the trash bag in the large trash bin located in the ISO 7 production room, rolling the bin into the ISO 8 anteroom, and resuming aseptic production activities in the ISO 5 hood after spraying her hands with <Redacted B4>. She did not change her sterile gloves or sleeves although they had been in contact with the trash bin. On 11/19/2019, she was also observed to spray and wipe down the foldable step-stool, which she uses to reach within the hood during cleaning and production, without changing her sterile gloves before resuming aseptic production activities.

Observation 3

Personnel engaged in aseptic processing were observed with exposed skin in critical areas. Specifically, on 11/18/2019 and 11/19/2019, the technician was observed with her forehead exposed while leaning significantly into the ISO 5 certified Hood <Redacted B4> during aseptic production activities.

Observation 4

Equipment, materials, and/or supplies are not disinfected prior to entering aseptic processing areas. Specifically, materials are not adequately disinfected prior to moving them from areas of lower to stricter classifications. Large drug components, such as , <Redacted B4> are "washed" in baskets in a <Redacted B4> loaded with <Redacted B4> and then partially dried using a <Redacted B4> located in the general pharmacy area prior to being placed in the <Redacted B4> to the ISO 7 production room. Materials are moved into temporary storage baskets within the ISO 7 room without disinfection. When they are used for production, materials are placed on ISO 5 worksurfaces prior to their disinfection within the hoods.

Observation 5

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations. Specifically, the media fills consist of preparing and <Redacted B4> media into <Redacted B4> control vials and <Redacted B4> vials intended to represent finished product, though this is not representative of the worst-case activities such as the manual production and <Redacted B4> of product in up to <Redacted B4> syringes intended for intracameral injections.

Observation 6

Disinfecting agents used in the ISO 5 area are not sterile. Specifically, <Redacted B4> is non-sterile and is routinely used for disinfection of the ISO 5 hoods and supporting aseptic processing areas.

Observation 7

Pressure differentials between areas with different air classifications were not monitored prior or during sterile drug production. Specifically, there is no verification of the pressure differentials before or during sterile drug production. Pressure differentials are measured with <Redacted B4> manometers which are not visible from within the cleanroom. The values are documented <Redacted B4> no time is recorded.

Observation 8

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess. Specifically, the <Redacted B4> and <Redacted B4> irrigation solutions have failed assay testing for epinephrine since 02/2019 but they were still produced and dispensed without resolving the failures. Additionally, testing data lacks supporting documentation with the date of production to verify the the assigned 9-day BUD is appropriate for the irrigation solutions.

Observation 9

The ISO-classified equipment have difficult-to-clean, particle-generating, or visibly dirty equipment or surfaces. Specifically, ISO 5 Hood <Redacted B4> has a worksurface composed of laminate which is worn and stained on the left side and has been chipped on both front corner edges. This hood is used for sterile drug production and was the only hood in use while Hood <Redacted B4> was down from about 10/31/2019 through 12/2/2019.

Observation 10

ISO-5 classified areas were not certified under dynamic conditions. Specifically, unidirectional airflow is not verified under operational conditions representative of the most challenging load and activities. The smoke studies performed only include evaluation of manual manipulations within the hood and do not include evaluation of a fully-loaded hood, such as with the <Redacted B4> equipment, which takes up a significant amount of space and potentially interrupts the first-pass air due to the <Redacted B4> airflow hood design.

State board of pharmacy records

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions in the data are dated January 2004 to April 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.